Core Insights - Spring Medical's stock price has increased by 121.32% year-to-date, with a recent 6.01% rise over the past five trading days [2] - The company reported a revenue of 756 million yuan for the first nine months of 2025, representing a year-on-year growth of 48.75%, and a net profit of 192 million yuan, up 213.21% year-on-year [3] Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices [2] - The company's main products include joint prosthetics and spinal implants, with a revenue composition of 99.89% from medical device products [2] Stock Performance - As of November 14, the stock price reached 28.22 yuan per share, with a market capitalization of 10.824 billion yuan [1] - The stock has shown significant price increases over various time frames: 6.01% over the last five days, 13.56% over the last 20 days, and 20.96% over the last 60 days [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average number of circulating shares per person decreased by 3.95% [3] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [4] Institutional Holdings - Notable new institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund, holding 2.9585 million shares and 2.8326 million shares, respectively [4] - The South China Medical Health Flexible Allocation Mixed Fund has exited the top ten circulating shareholders list [4]

证券之星消息，截至2025年11月13日收盘，春立医疗(688236)报收于27.66元，下跌1.21%，换手率 1.26%，成交量3.62万手，成交额1.01亿元。 11月13日的资金流向数据方面，主力资金净流入142.18万元，占总成交额1.41%，游资资金净流入 399.64万元，占总成交额3.97%，散户资金净流出541.82万元，占总成交额5.38%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-13 | 27.66 -1.21% | | 142.18万 | 1.41% | 399.64万 | 3.97% | -541.82万 | -5.38% | | 2025-11-12 | 28.00 | 3.36% | · 390.90万 | 3.92% | -549.05万 | -5.50% | 158.16万 | 1.59% | | 2025-11-11 | | 27.0 ...

证券之星消息，11月13日南向资金减持13.03万股春立医疗（01858.HK）。近5个交易日中，获南向资金 增持的有2天，累计净增持1.88万股。近20个交易日中，获南向资金增持的有14天，累计净增持211.97万 股。截至目前，南向资金持有春立医疗（01858.HK）4507.51万股，占公司已发行普通股的47.36%。 北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人 体关节。脊柱类植入产品为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非 洲、大洋洲及欧洲等多个国家和地区。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-13 | 4507.51万 | -13.03万 | -0.29% | | 2025-11-12 | 4520.53万 ...

Core Viewpoint - Spring Medical experienced a decline of 1.21% on November 13, with a trading volume of 101 million yuan and a market capitalization of 10.61 billion yuan [1] Group 1: Company Overview - Spring Medical is a leading domestic manufacturer of orthopedic medical devices, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company has developed a customized porous tantalum dental implant product, which is currently in the design and inspection phase [2] - Spring Medical's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, along with a full range of spinal internal fixation systems [2][5] Group 2: Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a year-on-year increase of 213.21% [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [8] Group 3: Market Position and Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [3] - The company is located in the Tongzhou Economic Development Zone in Beijing and was established on February 12, 1998, with its listing date on December 30, 2021 [7]

Core Viewpoint - Spring Medical experienced a 3.36% increase in stock price on November 12, with a trading volume of 99.78 million yuan, indicating strong market interest [1] Financing Summary - On November 12, Spring Medical had a financing buy-in amount of 10.89 million yuan and a financing repayment of 12.84 million yuan, resulting in a net financing buy of -1.95 million yuan [1] - As of November 12, the total financing and securities lending balance for Spring Medical was 55.28 million yuan, which accounts for 0.68% of its market capitalization, indicating a high financing balance compared to the past year [1] - The financing balance has exceeded the 90th percentile level over the past year, suggesting elevated investor activity [1] Company Overview - Beijing Spring Medical Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company was established on February 12, 1998, and went public on December 30, 2021 [2] - As of September 30, 2025, Spring Medical reported a revenue of 755.6 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% [2] Dividend and Shareholder Information - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2][3] - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund, both of which are new entrants among the top ten circulating shareholders [3]

Group 1 - The core viewpoint of the news is that Spring Medical has seen a stock price increase of 5.06%, reaching 28.46 CNY per share, with a total market capitalization of 10.916 billion CNY [1] - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants [1] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal internal fixation systems, with 99.89% of revenue coming from medical device products [1] Group 2 - From the perspective of major fund holdings, Guolian An Fund has a significant position in Spring Medical, with its Guolian An Stable Mixed A Fund increasing its holdings by 49,600 shares in the third quarter, now holding 347,300 shares, which constitutes 4.2% of the fund's net value [2] - The Guolian An Stable Mixed A Fund has achieved a year-to-date return of 28.4%, ranking 3140 out of 8147 in its category, and a one-year return of 20.89%, ranking 3203 out of 8056 [2]

Core Insights - Spring Medical (688236) closed at 27.09 yuan on November 11, 2025, down 3.25% with a trading volume of 29,400 hands and a transaction amount of 80.51 million yuan [1][2] Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, a year-on-year increase of 48.75% [4] - The net profit attributable to shareholders was 192 million yuan, up 213.21% year-on-year, while the net profit after deducting non-recurring gains and losses was 181 million yuan, an increase of 311.07% [4] - In Q3 2025, the company achieved a single-quarter main revenue of 268 million yuan, a year-on-year increase of 109.51%, and a net profit of 77.06 million yuan, up 531.12% year-on-year [4] Market Position - The total market value of Spring Medical is 10.39 billion yuan, ranking 37th in the medical device industry [4] - The company has a net asset of 2.99 billion yuan, ranking 51st, and a net profit of 192 million yuan, ranking 33rd [4] - The company's price-to-earnings ratio (P/E) is 40.69, which is lower than the industry average of 62.82, ranking 43rd [4] Investment Sentiment - In the last 90 days, 9 institutions rated the stock, with 8 buy ratings and 1 hold rating, and the average target price set by institutions is 30.65 yuan [5] - On November 11, 2025, the net inflow of main funds was 3.15 million yuan, accounting for 3.91% of the total transaction amount [1][2]

Trading Information Summary - On November 11, 2025, the stock of Chunli Medical (688236) closed at 27.09 CNY, down 3.25%, with a turnover rate of 1.02% and a trading volume of 29,400 shares, resulting in a transaction amount of 80.51 million CNY [1][2] - On the same day, the net inflow of main funds was 3.15 million CNY, accounting for 3.91% of the total transaction amount [2] Company Announcement Summary - Chunli Medical entered into three structured deposit agreements on November 11, 2025, using a total of 790 million CNY from temporarily idle funds raised from A-share public offerings and internal resources to subscribe to structured deposit products from Beijing Bank [1][2] - These transactions are classified as disclosable transactions but are exempt from shareholder approval [1][2] - The company acknowledged a prior failure to timely disclose related transactions and will enhance internal compliance management [1]

Core Viewpoint - Spring Medical (01858.HK) has entered into agreements with Beijing Bank for structured deposit products, utilizing temporary idle funds raised from its A-share public offering, totaling RMB 2.9 billion and RMB 2.1 billion for different branches [1] Company Summary - Spring Medical has agreed to invest a total of RMB 2.9 billion in structured deposits with Beijing Bank (Daxing Branch) and RMB 2.1 billion with Beijing Bank (Fangzhuang Branch) [1] - Additionally, the company will use internal resources to invest another RMB 2.9 billion in structured deposits with Beijing Bank (Fangzhuang Branch) [1] - As of November 11, 2025, Spring Medical's stock closed at HKD 19.12, with a slight increase of 0.21% and a trading volume of 860,000 shares, amounting to HKD 16.44 million [1] Industry Summary - Spring Medical's market capitalization is HKD 1.815 billion, ranking 17th in the medical device II industry [1] - Key performance indicators for Spring Medical compared to the industry average are as follows: - ROE: 5.6% vs. -4.03% (ranked 10th) - Market capitalization: HKD 1.815 billion vs. HKD 5.268 billion (ranked 17th) - Revenue: HKD 913 million vs. HKD 1.195 billion (ranked 10th) - Net profit margin: 23.48% vs. -16.5% (ranked 5th) - Gross margin: 67.09% vs. 54.89% (ranked 11th) - Risk rate: 16.62% vs. 29.03% (ranked 65th) [1]

春立医疗(01858)公布，于2025年11月11日，该公司订立(i)北京银行(大兴支行)结构性存款产品协议1， 同意使用其来自A股公开发行的临时闲置募集资金认购北京银行(大兴支行)的结构性存款产品，总金额 为人民币2.9亿元;(ii)北京银行(方庄支行)结构性存款产品协议1，同意使用其来自A股公开发行的临时闲 置募集资金认购北京银行(方庄支行)的结构性存款产品，总金额为人民币2.1亿元;及(iii)北京银行(方庄 支行)结构性存款产品协议2，同意使用其内部资源认购北京银行(方庄支行)的结构性存款产品，总金额 为人民币2.9亿元。 此外，于2025年9月26日，公司订立上海浦东发展银行(海淀园支行)结构性存款产品协议，同意使用其 内部资源认购上海浦东发展银行的结构性存款产品，总金额为人民币8500万元。上海浦东发展银行(海 淀园支行)结构性存款产品协议于本公告日期前已赎回。 ...